# Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer

> **NCT05251766** · PHASE1 · UNKNOWN · sponsor: **Xuli Meng** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Chemotherapy Effect

## Interventions

- **DRUG:** Nab paclitaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05251766
- **Lead sponsor:** Xuli Meng
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-20
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251766, "Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05251766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*